# Cyclophosphamide

## Endoxan Asta inj 200mg

| 藥物代碼 | IEND |
| :--- | :--- |
| 適應症 | Treatment of acute lymphoblastic leukemia \(ALL\), acute myelocytic leukemia \(AML\), breast cancer, chronic lymphocytic leukemia \(CLL\), chronic myeloid leukemia \(CML\), Hodgkin lymphoma, mycosis fungoides, multiple myeloma, neuroblastoma, non-Hodgkin lymphomas \(including Burkitt lymphoma\), ovarian adenocarcinoma, retinoblastoma, and nephrotic syndrome. |
| 副作用 | GI upsets; alopecia; reticulo-endothelial system depression; hematuria; reversible amenorrhea & azoospermia; myocardial damage with very high doses; pigmentation, macrocytosis, water retention; induction of hyperglycemia or hypoglycemia; risk of secondary malignancies. |
| 禁忌 | Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection \(especially varicella zoster\), severe immunosuppression. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Initial treatment Generally by IV inj. Dosage must be strictly individual, taking into consideration the general state of the patient & his WBC. Daily IV inj: 3-6 mg/kg body weight \(200-400 mg/m2\), or Massive-intermittent therapy: 10-15 mg/kg body weight \(500-1000 mg/m2\) with therapy-free intervals of 2 or 5 days, or Massive-intermittent therapy: 20-40 mg/kg body weight with therapy-free intervals of 10-20 days Continuation or maintenance therapy 50-200 mg/day orally |
| 肝功能異常 | 需 調 整 劑 量  血清膽紅素值為3.1-5mg/100ml者，降低25%的劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【N/S】 可選  【D5W】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC。 3. 定期尿液檢測，注意血尿。 |

## Endoxan 50mg

| 藥物代碼 | OEND |
| :--- | :--- |
| 適應症 | Treatment of acute lymphoblastic leukemia \(ALL\), acute myelocytic leukemia \(AML\), breast cancer, chronic lymphocytic leukemia \(CLL\), chronic myeloid leukemia \(CML\), Hodgkin lymphoma, mycosis fungoides, multiple myeloma, neuroblastoma, non-Hodgkin lymphomas \(including Burkitt lymphoma\), ovarian adenocarcinoma, retinoblastoma, and nephrotic syndrome. |
| 副作用 | Nausea, vomiting; bone marrow depression, leukopenia; alopecia; mucosal ulceration; pigmentation; interstitial pulmonary fibrosis; fluid retention |
| 禁忌 | Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection \(especially varicella zoster\), severe immunosuppression. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Should be taken on an empty stomach \(Preferably taken on an empty stomach, but may be taken w/ meals to minimise GI irritation. Ensure adequate fluid intake. Swallow whole.\). Adult 0.2-0.4 mg daily up to a total dose of 4-8 g, followed by PO maintenance therapy with doses ranging from 0.2-0.5 g daily. |
| 肝功能異常 | 需 調 整 劑 量  嚴重肝功能不全患者須降低劑量,血清膽紅素值 3.1 - 5 mg/100ml者,降低25%的劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

